Epalrestat is a selective aldose reductase inhibitor. Since its approval in Japan in 1992, it has become an important therapeutic agent for diabetic peripheral neuropathy.
Dosage and Administration of Epalrestat: Recommended Dosage
Routine Dosing Regimen
The recommended dosage for adults is usually 50 mg (1 tablet) per dose, three times a day, to be taken orally before each meal.
The drug is in the form of white film-coated tablets, with a diameter of 6.7 mm, a thickness of 3.9 mm, and a weight of approximately 120 mg. The surface of each tablet is engraved with the identification code "NF611".
Administration Precautions
It is particularly emphasized that the drug is packaged in PTP (Press-Through Package) aluminum foil, and the tablets must be removed from the packaging before administration.
If the aluminum foil blister is accidentally swallowed, its rigid sharp edges may damage the esophageal mucosa; in severe cases, this can lead to esophageal perforation and concurrent mediastinitis.
During the medication period, urine may appear yellowish-brown or red. This phenomenon may interfere with the accuracy of qualitative test results for urinary bilirubin and ketone bodies.
Dosage Adjustment of Epalrestat
Principles of Individualized Adjustment
In clinical practice, the dosage should be appropriately adjusted based on the patient’s age and the severity of symptoms.
For elderly patients or those with mild symptoms, it is advisable to start with a lower dose and gradually adjust to the optimal therapeutic dose.
Efficacy Evaluation and Regimen Optimization
Changes in the patient’s condition should be closely monitored during treatment.
If no significant therapeutic effect is observed after 12 consecutive weeks of medication, it is recommended to re-evaluate the diagnosis and consider switching to another treatment regimen.
The efficacy of Epalrestat has not been established in diabetic patients with irreversible organic lesions, and the drug should be used with caution in such cases.
Use of Epalrestat in Special Populations
Pregnant and Lactating Women
Pregnant women or women who may become pregnant should use this drug only when the clear therapeutic benefits outweigh the potential risks.
Lactating women should comprehensively assess the necessity of treatment and decide whether to continue breastfeeding or discontinue the drug.
Animal studies have shown that the drug can be excreted in breast milk, so the benefits and risks must be carefully weighed.
Children and Patients with Hepatic or Renal Impairment
No clinical trials in children have been conducted so far; the efficacy of the drug in children has not been established, and its use in this population is not recommended.
The package insert does not provide clear guidance for patients with renal impairment.
Special attention should be paid to patients with hepatic impairment: since liver dysfunction is a known side effect of this drug, liver function indicators should be closely monitored during the medication period.
Populations in Special Physiological States
For men and women of reproductive potential, the package insert does not specify precautions for medication use. Clinical use should be based on individual conditions and decided with caution.
